Katherine Goodrich's most recent trade in Tarsus Pharmaceuticals Inc was a trade of 3,837 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 25, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharma Inc | Katherine Goodrich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2026 | 3,837 | 3,837 | - | - | Stock Option (right to buy) | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2026 | 2,417 | 2,417 | - | - | Restricted Stock Units | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Sale of securities on an exchange or to another person at price $ 62.08 per share. | 15 Jun 2026 | 2,954 | 2,233 | - | 62.1 | 183,384 | Common Stock |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2026 | 2,954 | 0 | - | - | Restricted Stock Units | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2026 | 2,954 | 5,187 | - | - | Common Stock | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 2,233 | 2,233 | - | - | Common Stock | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 2,233 | 4,467 | - | - | Restricted Stock Units | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 4,540 | 4,540 | - | - | Stock Option (right to buy) | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 2,954 | 2,954 | - | - | Restricted Stock Units | |
| Tarsus Pharma Inc | Katherine Goodrich | Director | 13 Nov 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | ||
| Tarsus Pharma Inc | Katherine Goodrich | Director | 13 Nov 2024 | 6,700 | 6,700 | - | - | Restricted Stock Units |